Kristin Higgins, MD, City of Hope

home / authors / kristin-higgins-md-city-of-hope

Articles

Multidisciplinary Management of Patients With Stage III NSCLC

Multidisciplinary Management of Patients With Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center;Kristin Higgins, MD, City of Hope;Brendon M. Stiles, MD
July 13th 2020

Read More

Integrating Perioperative Immunotherapy Strategies in NSCLC

Integrating Perioperative Immunotherapy Strategies in NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center;Kristin Higgins, MD, City of Hope;Brendon M. Stiles, MD
July 13th 2020

Read More

Molecular testing in Patients With Metastatic NSCLC

Molecular testing in Patients With Metastatic NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center;Kristin Higgins, MD, City of Hope;Brendon M. Stiles, MD
July 13th 2020

Read More

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center;Kristin Higgins, MD, City of Hope;Brendon M. Stiles, MD
July 13th 2020

Read More

Varied Timing of IO Therapy in Patients With Stage III NSCLC

Varied Timing of IO Therapy in Patients With Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center;Kristin Higgins, MD, City of Hope;Brendon M. Stiles, MD
July 13th 2020

Read More

Treating for Stage III NSCLC After Progression on Durvalumab

Treating for Stage III NSCLC After Progression on Durvalumab

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center;Kristin Higgins, MD, City of Hope;Brendon M. Stiles, MD
July 13th 2020

Read More

Durvalumab in Stage III NSCLC Based on Performance Status

Durvalumab in Stage III NSCLC Based on Performance Status

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center;Kristin Higgins, MD, City of Hope;Brendon M. Stiles, MD
July 13th 2020

Read More

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center;Kristin Higgins, MD, City of Hope;Brendon M. Stiles, MD
July 13th 2020

Read More

Mediastinal Staging in Non–Small Cell Lung Cancer

Mediastinal Staging in Non–Small Cell Lung Cancer

Mark A. Socinski, MD, AdventHealth Cancer Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center;Kristin Higgins, MD, City of Hope;Brendon M. Stiles, MD
July 13th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need